Aptorum Group Ltd Class A (APM)vsInsmed Inc (INSM)
APM
Aptorum Group Ltd Class A
$1.12
-3.10%
HEALTHCARE · Cap: $8.80M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
APM leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
APM
Avoid24
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : APM
The strongest argument for APM centers on Price/Book, Debt/Equity.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : APM
The primary concerns for APM are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
APM profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
APM generates stronger free cash flow (-484,283), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aptorum Group Ltd Class A
HEALTHCARE · BIOTECHNOLOGY · USA
Aptorum Group Limited, a pharmaceutical company, is dedicated to the discovery, development and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. The company is headquartered in London, the United Kingdom.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?